Manufacturesd by a Basque biotechnology company, Progenika Biopharma - BLOODchip® - is a DNA biochip which greatly eliminates the risk of adverse reactions due to incompatibility in blood groups between donor and receptor in blood transfusions.

With the aim of guaranteeing safety during blood transfusions, Progenika has developed and validated 1,000 clinical samples in cooperation with the principal European blood banks. Concretely, the validation of these samples was 99.8%, considerably higher than that produced using the current serology technique, which produces an error of 3%.

The BLOODchip® is the result of research within the remit of the European Union IV Framework Programme and undertaken by Progenika in collaboration with the principal European blood banks.

Currently, BLOODchip® is the safest and most precise technique for genetically determining blood groups, enabling the reduction of adverse reactions in blood transfusions.

Find more details from the full report.

[Photo Credit: Progenika Biopharma]